COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Join the next COVID-19 Webinar
Join thousands of your peers in WCG’s online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from April 9, 2021
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
Advisory Panel Meets Today to Discuss Rare Blood Clots in Patients Given J&J Vaccine
An expert panel of the Centers for Disease Control and Prevention (CDC) is meeting today to review blood-clot incidents reported in a handful of patients who received Johnson & Johnson’s (J&J) one-dose COVID-19 vaccine.
Moderna’s COVID-19 Vaccine Effective After Six Months, Phase 3 Trial Data Shows
New data from Moderna’s phase 3 COVID-19 vaccine trial have shown that the U.S. drugmaker’s two-dose inoculation remains highly effective against the virus six months after the second shot, including for severe infection, the company said Tuesday.
Gilead Halts Phase 3 Remdesivir Study in High-Risk Nonhospitalized COVID-19 Patients
Patients already participating in the study will continue to be assessed, the company said, adding it is developing an experimental inhaled formulation of the antiviral.
Rigel’s Fostamatinib Hits Mark in Phase 2 Trial of Hospitalized COVID-19 Patients
Patients given fostamatinib saw a more rapid decline in inflammatory biomarkers compared to those receiving placebo.
India Authorizes Emergency Use of Russia’s Sputnik V Vaccine
The Indian government and the Russian Direct Investment Fund reached an agreement that will allow Indian companies to produce 850 million doses of the vaccine per year.
Health Canada Introduces New Reporting Requirements to Reduce Shortages
Once a product is on the authorized list, companies must notify the agency at least five business days before they import a designated device.
Johnson & Johnson Begins European Deliveries of COVID-19 Vaccine
In a much-needed development, Johnson & Johnson began delivery of its one-shot COVID-19 vaccine within the EU yesterday as the trade bloc continues to clamor for enough doses to inoculate its 446 million residents.
Regeneron’s COVID-19 Antibody Combo Cuts Symptomatic Infections
Regeneron Pharmaceuticals has said its COVID-19 antibody cocktail, REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic infections by 81 percent in a late-stage trial.
Eli Lilly to Supply Bamlanivimab Only as Combination Therapy to U.S. Government
Eli Lilly has revised its supply deal with the U.S. government to focus on distributing the company’s COVID-19 antibody bamlanivimab along with another antibody, etesevimab — a combination that has proven to be effective against variant strains of the Sars-CoV-2 virus which causes COVID-19 infections.
AstraZeneca’s Farxiga Falters in Phase 3 COVID-19 Trial
AstraZeneca’s heart failure and diabetes drug Farxiga (dapagliflozin) failed to meaningfully reduce the risk of organ dysfunction and death for high-risk, hospitalized COVID-19 patients in a phase 3 study.
FDA Clears Lucira Health’s COVID-19 Diagnostic for Over-the-Counter Use
The over-the-counter test can be purchased online from the company for $55.
White House Official: Emergent’s Bayview Facility Could Be Authorized This Month
Emergent BioSolutions’ beleaguered Baltimore, Md., facility, which Johnson & Johnson has taken over to exclusively produce its vaccine, may be cleared to start shipping out J&J doses before the month is over, according to the White House’s COVID-19 response leader.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.